D-dimer is an important biomarker used to assess the risk of a person developing a deep vein thrombosis (DVT) or pulmonary embolism (PE). It is a short fragment of a protein called fibrin that is produced by the body during the clotting process. The presence of elevated levels of D-dimer in the blood can indicate an increased risk of developing a DVT or PE, and can be used to help diagnose and treat these conditions. However, the normal ranges of D-dimer can vary greatly depending on a person’s age. It is important for doctors to understand the normal ranges of D-dimer by age in order to accurately assess a patient’s risk of developing a DVT or PE. This guide will provide an overview of D-dimer normal ranges by age, and discuss how these ranges can be used to assess a patient’s risk of developing a DVT or PE.
D-dimer is a protein fragment produced by the body during the clotting process. It is a short fragment of a larger protein called fibrin, which is produced when the body's clotting factors are activated. D-dimer is released into the bloodstream when a clot is being formed, and its levels can be measured in a blood test. The presence of elevated levels of D-dimer in the blood can indicate an increased risk of developing a DVT or PE. This is because elevated levels of D-dimer can indicate that a clot is forming in the veins or arteries, which can lead to a DVT or PE.
The normal ranges of D-dimer vary greatly depending on a person’s age. In general, the normal range of D-dimer is lower in younger individuals and increases with age. For adults aged 18-50, the normal range of D-dimer is typically 0-0.5 mcg/mL. For adults aged 50-75, the normal range is typically 0.5-1.0 mcg/mL. For adults aged 75 and older, the normal range is typically 1.0-2.0 mcg/mL. In addition to age, other factors can affect the normal range of D-dimer, such as gender, body weight, and health conditions. For example, women tend to have higher levels of D-dimer than men, and people with certain health conditions, such as cancer, may have higher levels of D-dimer than those without the condition.
D-dimer normal ranges can be used to assess a person’s risk of developing a DVT or PE. If a person’s D-dimer levels are higher than the normal range for their age, it may indicate an increased risk of developing a DVT or PE. In addition, doctors can use D-dimer normal ranges to help diagnose a DVT or PE. If a person has a D-dimer level that is higher than the normal range for their age, it may indicate that they have a DVT or PE.
D-dimer is an important biomarker used to assess the risk of a person developing a deep vein thrombosis (DVT) or pulmonary embolism (PE). The normal ranges of D-dimer vary greatly depending on a person’s age, and it is important for doctors to understand these ranges in order to accurately assess a patient’s risk of developing a DVT or PE. D-dimer normal ranges can also be used to help diagnose a DVT or PE. By understanding D-dimer normal ranges by age, doctors can more accurately assess a patient’s risk of developing a DVT or PE.
1.
Q&A: When will individuals be able to receive customized cancer vaccines?
2.
Canadian Group Calls for Earlier Colorectal Cancer Screening
3.
Children living near oil and gas wells face higher risk of rare leukemia, studies show
4.
Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.
5.
Talquetamab Combos Show Survival Benefit in r/r Myeloma
1.
Liquid Biopsy: A Revolutionary Tool for Early Detection and Monitoring of Colorectal Cancer
2.
Clinical Pharmacology of Megakaryocyte Maturation-Targeted Therapeutics
3.
The Benefits and Side Effects of Bortezomib in the Fight Against Cancer
4.
Personalized Tumor Ecological Landscapes in Oncology
5.
Unmasking the Subtle Symptoms of Colon Cancer
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Immunotherapy: A New Era in Cancer Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation